Supreme Court to examine a common legal strategy drug makers use to sidestep patient lawsuits

first_img WASHINGTON — The Supreme Court will next week consider a case that has the potential to upend how drug companies can defend themselves from patient lawsuits.The case, Merck Sharp & Dohme Corp. v. Doris Albrecht, began as a collection of lawsuits by more than a thousand patients who used the osteoporosis drug Fosamax. The patients say the drug maker failed to adequately warn them that taking the drug might make them more likely to fracture their femurs. What’s included? Jon Elswick/AP GET STARTED Supreme Court to examine a common legal strategy drug makers use to sidestep patient lawsuits Politics Log In | Learn More What is it? STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Tags courtslegalpharmaceuticalspolicySTAT+Supreme Court Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. By Ike Swetlitz Jan. 3, 2019 Reprints Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+. First 30 days free. GET STARTEDlast_img read more

Read More »